+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Dihydroorotate dehydrogenase inhibitors - Pipeline Insight, 2024

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • January 2024
  • Region: Global
  • DelveInsight
  • ID: 4382734
UP TO OFF until Dec 31st 2024
This “Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Understanding

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview

Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as acute myeloid leukemia, RA, multiple sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 treatment using DHODH inhibitors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dihydroorotate Dehydrogenase (DHODH) Inhibitor R&D. The therapies under development are focused on novel approaches for Dihydroorotate Dehydrogenase (DHODH) Inhibitor.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs Chapters

This segment of the Dihydroorotate Dehydrogenase (DHODH) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs

IMU-838: Immunic IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019infections.

PTC 299: PTC Therapeutics Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Dihydroorotate Dehydrogenase (DHODH) Inhibitor

There are approx. 10+ key companies which are developing the Dihydroorotate Dehydrogenase (DHODH) Inhibitor. The companies which have their Dihydroorotate Dehydrogenase (DHODH) Inhibitor drug candidates in the most advanced stage, i.e. Phase II/III include, Immunic

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Insights

  • Dihydroorotate Dehydrogenase (DHODH) Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs?
  • How many Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Dihydroorotate Dehydrogenase (DHODH) Inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dihydroorotate Dehydrogenase (DHODH) Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Sanofi
  • Immunic
  • PTC Therapeutics
  • Clear Creek Bio
  • Eye GatePharma
  • ASLAN Pharmaceuticals
  • Medicines for Malaria Venture

Key Products

  • Teriflunomide
  • IMU-838
  • Emvododstat
  • Olorofim
  • Brequinar
  • PP 001 Eye GatePharma
  • ASLAN-003
  • MMV-1793609


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Analytical Perspective
In-depth Commercial Assessment
  • Dihydroorotate Dehydrogenase (DHODH) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
  • Comparative Analysis
IMU-838: Immunic
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  • Comparative Analysis
PP 001: EyeGate Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
MMV-1793609: Medicines for Malaria Venture
  • Product Description
  • Research and Development
  • Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  • Comparative Analysis
Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key CompaniesDihydroorotate Dehydrogenase (DHODH) Inhibitor Key ProductsDihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet NeedsDihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and BarriersDihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and ConclusionDihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst ViewsDihydroorotate Dehydrogenase (DHODH) Inhibitor Key CompaniesAppendix
List of Tables
Table 1Total Products for Dihydroorotate dehydrogenase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Dihydroorotate dehydrogenase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sanofi
  • Immunic
  • PTC Therapeutics
  • Clear Creek Bio
  • EyeGate Pharma
  • ASLAN Pharmaceuticals
  • Medicines for Malaria Venture